Pfizer and OPKO announced Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to treat children with Gr false

אופקו הלת', אינק	2 380
OPKO HEALTH, INC
Corporation no: 2279206	10802

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	08/10/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-109971	Time of broadcast: 18:50 18:50

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

Pfizer and OPKO announced Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to treat children with Growth Hormone Deficiency פייזר ואופקו הודיעו על הצלחת ניסוי בסומטרוגון לטיפול בילדים הסובלים מ- GHD

20201008PRSigned.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: NASDAQ GSM	Date of revision of form structure: 04/08/2020
Address: Ashlegan 16 , Kiryat Gat 8211804   Israel , Tel: 08-9300051 , Fax: 08-9300091
E-mail address: yphilip@opko.com   Company site: Www.Opko.Com
Previous names of reporting entity:
Name of the Signatory: Philip Yifat Position of Signatory in the reporting corporation: General Counsel Name of Employer Company:
Address: Golda Meir 7 , Nes Ziona 7414002 Telephone: 08-9300051 Facsimile: 08-9300091 E-mail: yphilip@opko.com 1